Current status of therapy for breast cancer worldwide and in Japan

doi:10.5306/wjco.v2.i2.125

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6769)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-14) series, Tables (1-3) series.

Item

Count

PDF

592

HTML

5747

Figures (1-14)

209

Tables (1-3)

221

Sum=6769

Feb 10, 2011 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Feb 10, 2011; 2(2): 125-134
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.125

Full Size Figure Download Figure

Figure 14 Phase III trial of paclitaxel plus bevacizumab vs paclitaxel alone for metastatic breast cancer. Progression-free survival (PFS) (median, 11.8 mo vs 5.9 mo, hazard ratio = 0.60). (Source: Figure 2A in reference 21).

Citation: Park Y, Kitahara T, Takagi R, Kato R. Current status of therapy for breast cancer worldwide and in Japan. World J Clin Oncol 2011; 2(2): 125-134
URL: https://www.wjgnet.com/2218-4333/full/v2/i2/125.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i2.125